GB201519406D0 - Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer - Google Patents

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Info

Publication number
GB201519406D0
GB201519406D0 GBGB1519406.1A GB201519406A GB201519406D0 GB 201519406 D0 GB201519406 D0 GB 201519406D0 GB 201519406 A GB201519406 A GB 201519406A GB 201519406 D0 GB201519406 D0 GB 201519406D0
Authority
GB
United Kingdom
Prior art keywords
quinolin
imidazo
compounds
treating cancer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1519406.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB1519406.1A priority Critical patent/GB201519406D0/en
Publication of GB201519406D0 publication Critical patent/GB201519406D0/en
Priority to EP16790601.5A priority patent/EP3371183A1/en
Priority to MX2018005445A priority patent/MX2018005445A/es
Priority to PE2018000612A priority patent/PE20181345A1/es
Priority to CA3002608A priority patent/CA3002608A1/en
Priority to BR112018007772A priority patent/BR112018007772A2/pt
Priority to JP2018522026A priority patent/JP2018536649A/ja
Priority to HK19100042.7A priority patent/HK1257678A1/zh
Priority to PCT/EP2016/076412 priority patent/WO2017076895A1/en
Priority to KR1020187015448A priority patent/KR20180070703A/ko
Priority to AU2016348546A priority patent/AU2016348546B2/en
Priority to RU2018120318A priority patent/RU2018120318A/ru
Priority to CR20180307A priority patent/CR20180307A/es
Priority to CN201680063688.5A priority patent/CN108349971A/zh
Priority to US15/772,118 priority patent/US20180318287A1/en
Priority to HK18114727.1A priority patent/HK1255598A1/zh
Priority to SV2018005663A priority patent/SV2018005663A/es
Priority to CONC2018/0003969A priority patent/CO2018003969A2/es
Priority to IL258818A priority patent/IL258818A/en
Priority to CL2018001146A priority patent/CL2018001146A1/es
Priority to PH12018500958A priority patent/PH12018500958A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1519406.1A 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer Ceased GB201519406D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK18114727.1A HK1255598A1 (zh) 2015-11-03 2016-11-02 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
AU2016348546A AU2016348546B2 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CR20180307A CR20180307A (es) 2015-11-03 2016-11-02 Compuestos de imidazo[4,5-c] quinolin-2-ona y su uso en el tratamiento del cáncer
PE2018000612A PE20181345A1 (es) 2015-11-03 2016-11-02 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
CA3002608A CA3002608A1 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
BR112018007772A BR112018007772A2 (pt) 2015-11-03 2016-11-02 compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
JP2018522026A JP2018536649A (ja) 2015-11-03 2016-11-02 イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用
HK19100042.7A HK1257678A1 (zh) 2015-11-03 2016-11-02 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
PCT/EP2016/076412 WO2017076895A1 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
KR1020187015448A KR20180070703A (ko) 2015-11-03 2016-11-02 이미다조[4,5-c]퀴놀린-2-온 화합물 및 암 치료에서의 이의 용도
EP16790601.5A EP3371183A1 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
RU2018120318A RU2018120318A (ru) 2015-11-03 2016-11-02 ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2018005445A MX2018005445A (es) 2015-11-03 2016-11-02 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer.
CN201680063688.5A CN108349971A (zh) 2015-11-03 2016-11-02 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
US15/772,118 US20180318287A1 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
SV2018005663A SV2018005663A (es) 2015-11-03 2018-04-06 Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CONC2018/0003969A CO2018003969A2 (es) 2015-11-03 2018-04-13 Compuestos de imidazo[4,5-c]quinolin-2-ona
IL258818A IL258818A (en) 2015-11-03 2018-04-22 Imidazo[4,5-c]quinolin-2-ion compounds and their use in cancer treatment
CL2018001146A CL2018001146A1 (es) 2015-11-03 2018-04-30 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
PH12018500958A PH12018500958A1 (en) 2015-11-03 2018-05-03 Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
GB201519406D0 true GB201519406D0 (en) 2015-12-16

Family

ID=55130605

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1519406.1A Ceased GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Country Status (20)

Country Link
US (1) US20180318287A1 (enExample)
EP (1) EP3371183A1 (enExample)
JP (1) JP2018536649A (enExample)
KR (1) KR20180070703A (enExample)
CN (1) CN108349971A (enExample)
AU (1) AU2016348546B2 (enExample)
BR (1) BR112018007772A2 (enExample)
CA (1) CA3002608A1 (enExample)
CL (1) CL2018001146A1 (enExample)
CO (1) CO2018003969A2 (enExample)
CR (1) CR20180307A (enExample)
GB (1) GB201519406D0 (enExample)
HK (2) HK1255598A1 (enExample)
IL (1) IL258818A (enExample)
MX (1) MX2018005445A (enExample)
PE (1) PE20181345A1 (enExample)
PH (1) PH12018500958A1 (enExample)
RU (1) RU2018120318A (enExample)
SV (1) SV2018005663A (enExample)
WO (1) WO2017076895A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
ES3001444T3 (en) 2018-09-14 2025-03-05 Suzhou Zanrong Pharma Ltd 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
EP3845532B1 (en) * 2018-09-30 2022-12-21 Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivative and application thereof
SG11202109451TA (en) * 2019-03-05 2021-09-29 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
CN116056698B (zh) * 2020-09-21 2024-11-19 威尚（上海）生物医药有限公司 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
WO2023143282A1 (zh) * 2022-01-26 2023-08-03 正大天晴药业集团股份有限公司 含有肼基的化合物
US20250179067A1 (en) * 2022-04-11 2025-06-05 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311714A1 (en) * 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
RS62082B1 (sr) * 2015-04-02 2021-08-31 Merck Patent Gmbh Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze

Also Published As

Publication number Publication date
SV2018005663A (es) 2018-07-20
MX2018005445A (es) 2018-08-14
KR20180070703A (ko) 2018-06-26
CN108349971A (zh) 2018-07-31
US20180318287A1 (en) 2018-11-08
CL2018001146A1 (es) 2018-09-04
CO2018003969A2 (es) 2018-07-10
RU2018120318A (ru) 2019-12-05
CR20180307A (es) 2018-10-05
WO2017076895A1 (en) 2017-05-11
JP2018536649A (ja) 2018-12-13
PE20181345A1 (es) 2018-08-22
RU2018120318A3 (enExample) 2019-12-24
CA3002608A1 (en) 2017-05-11
EP3371183A1 (en) 2018-09-12
AU2016348546A1 (en) 2018-06-14
PH12018500958A1 (en) 2018-11-19
HK1257678A1 (zh) 2019-10-25
BR112018007772A2 (pt) 2018-10-30
AU2016348546B2 (en) 2019-05-02
IL258818A (en) 2018-06-28
HK1255598A1 (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
IL258818A (en) Imidazo[4,5-c]quinolin-2-ion compounds and their use in cancer treatment
IL248397B (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL258828A (en) Imidazo[4,5-c]quinolin-2-ion compounds and their use in cancer therapy
GB201516504D0 (en) Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
GB201608227D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL266245B (en) History of 9,8,7,6-tetrahydro-3h-pyrazolo[3,4-f]isoquinoline useful in cancer treatment
SG10201913538VA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
ZA201807810B (en) Adenosine derivatives for use in the treatment of cancer
IL266198A (en) Liposomal formulation for use in cancer treatment
IL269272A (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201604182D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL262656A (en) Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
HK1255487A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK40091842A (zh) 用於癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
HK40022419A (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201516220D0 (en) Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer
HK1259160A1 (en) Bis-pyridazine compounds and their use in treating cancer
GB201613403D0 (en) Pyrrolo[2,3-d]pyrimidin-4-amine compounds and their use in treating cancer
HK1260394A1 (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)